Open an account

Neurosense Therapeutics

NRSN · NASDAQ

$2.39−$0.275 (−10.32%)TodayMarket closed ·
Prev close $2.67

About NRSN

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Employees
16
Headquarters
Herzliya
Listed
Dec 9, 2021
Sector
Health Care
Industry
Biotechnology
Website
neurosense-tx.com

NRSN key statistics

Market cap
4.53M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
25.42K
Volume
13.85K
Open price
$2.74
High today
$2.74
Low today
$2.19
52 Week high
$26.64
52 Week low
$2.36

Neurosense Therapeutics (NRSN) at a glance

Neurosense Therapeutics (NRSN) last traded at $2.39, with a market cap of 4.53M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.19 and $2.74. The current price is 9.1% above the day's low and 12.8% below its high.

Volume so far is 13.85K shares, below the average of 25.42K shares a day.

Over the past year Neurosense Therapeutics has ranged from $2.36 to $26.64, and now sits 0% of the way up that range.

Neurosense Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY25 it reported -$0.19 per share against an estimate of -$0.204.

The average analyst price target is $112.71, 4615.9% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $112.71
Low
$52.52
Now
$2.39
High
$189.00

NRSN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 56.7% on average.

  1. Q2 FY23: reported -$0.44 per share against an estimate of -$0.2856
  2. Q3 FY23: reported $0.10 per share against an estimate of -$0.2499
  3. Q4 FY23: reported -$0.16 per share against an estimate of -$0.204
  4. Q1 FY24: reported -$0.35 per share against an estimate of -$0.2091
  5. Q2 FY24: reported -$0.02 per share against an estimate of -$0.204
  6. Q3 FY24: reported -$0.11 per share against an estimate of -$0.1632
  7. Q4 FY24: reported -$0.06 per share against an estimate of -$0.1173
  8. Q2 FY25: reported -$0.19 per share against an estimate of -$0.204

NRSN news

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releasePRNewswire

    NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

  • Press releasePRNewswire

    NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

  • Press releasePRNewswire

    NeuroSense Provides Update on Nasdaq Listing Compliance

  • Press releasePRNewswire

    NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

  • Press releasePRNewswire

    NeuroSense Provides Business Update and Progress for the First Half of 2026

  • Press releasePRNewswire

    NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

  • 12 Health Care Stocks Moving In Friday's Intraday Session

Similar companies

Companies in the same industry as Neurosense Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.